Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belimumab and Rituximab Combination Therapy for Diffuse Cutaneous Systemic Sclerosis
NCT03844061Phase 2Active, not recruiting
- Sponsor
- Hospital for Special Surgery
- Start
- Jul 2019
- Primary completion
- Aug 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of belimumab, rituximab in systemic sclerosis (SSc), sponsored by Hospital for Special Surgery. Started Jul 2019; status: active, not recruiting.
02
Drugs
belimumabrituximab
03
Conditions
systemic sclerosis (SSc)
Beyond the preview
Go deeper on NCT03844061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03844061.